// App-Quantinova.ai

BSH2020‐PO‐058 : Ruxolitinib in myelofibrosis: a multicentre analysis of real‐world patients in England, Northern Ireland and Wales

Researchers

Presenter

  • J. Russell

Principal Investigators

  • D. Sparksman

  • D. Waddell

  • A. Daly

  • R. Fisken

  • A. Dicu

  • J. Cunningham

  • S. Docherty

  • C. Saha

  • I. Lentell

  • Y. J. Lim

  • K. Maw

  • A. Fowler

  • S. Knapper

  • A. Collins

  • N. Butt

  • F. Wadelin

  • I. Whalley

  • E. Gudgin

  • A. Godfrey

  • M. F. McMullin

  • S. Sadullah

Medical Centers

  • Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge

  • Haematology, Norfolk and Norwich University Hospital NHS Foundation Trust, London

  • Haematology,Belfast City Hospital,Belfast,Regno Unito

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Oncology, Nottingham University Hospital, Nottingham, UK

  • Haematology, James Paget University Hospitals NHS Foundation Trust, Gorleston on sea, United Kingdom

  • Haematology, West Suffolk Hospital, Bury Saint Edmunds

  • Clinical Haematology, Royal Liverpool University Hospital, Liverpool, UK

  • Immunology, Peterborough City Hospital, Peterborough, UK

  • Rheumatology, University Hospital of Wales, Cardiff, UK

  • Haematology, Ipswich Hospital, Ipswich

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

  • Oncology (ONC)

Disease

  • Myeloid neoplasms

  • Essential thrombocythemia

  • Acute myelocytic leukemia

  • Myocardial infarction

  • Polycythaemia vera

  • Myelofibrosis

  • Solid malignancies

Biomarkers

  • MPL proto-oncogene, thrombopoietin receptor

  • Calreticulin

  • Janus kinase

Drug/Treatment

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • Multinational

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved